We are live on ! Find out more
FLSM

Frazier Life Sciences Management Portfolio holdings

AUM $4.59B
1-Year Est. Return 237.58%
This Fund
S&P 500
This Quarter Est. Return
+25.98%
1 Year Est. Return
+237.58%
3 Year Est. Return
+865.83%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.67B
AUM Growth
+$293M
Cap. Flow
+$59.1M
Cap. Flow %
3.53%
Top 10 Hldgs %
66.82%
Holding
53
New
4
Increased
12
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
IRON icon
Disc Medicine
IRON
+$23.2M
2
NAMS icon
NewAmsterdam Pharma
NAMS
+$20.3M
3
PHAT icon
Phathom Pharmaceuticals
PHAT
+$19.6M
4
MIRM icon
Mirum Pharmaceuticals
MIRM
+$13.3M
5
BBIO icon
BridgeBio Pharma
BBIO
+$12.3M

Top Sells

Rank Stock Value
1
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$11.6M
2
PCVX icon
Vaxcyte
PCVX
+$11M
3
RNAM
Avidity Biosciences
RNAM
+$7.67M
4
COGT icon
Cogent Biosciences
COGT
+$7.55M
5
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$168M 10.04%
9,781,472
– –
KDNY
2
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$167M 9.97%
4,345,559
– –
PHAT icon
3
Phathom Pharmaceuticals
PHAT
$743M
$145M 8.65%
10,109,279
+1,702,127
+20% +$19.6M
NAMS icon
4
NewAmsterdam Pharma
NAMS
$3.1B
$129M 7.72%
10,871,803
+1,530,252
+16% +$20.3M
KRYS icon
5
Krystal Biotech
KRYS
$10.4B
$116M 6.94%
990,260
+44,853
+5% +$4.58M
MIRM icon
6
Mirum Pharmaceuticals
MIRM
$5.94B
$113M 6.74%
4,360,107
+500,000
+13% +$13.3M
ARQT icon
7
Arcutis Biotherapeutics
ARQT
$2.99B
$82.8M 4.94%
8,684,232
– –
SNDX icon
8
Syndax Pharmaceuticals
SNDX
$1.74B
$77.6M 4.64%
3,708,838
– –
VRNA
9
DELISTED
Verona Pharma
VRNA
$62.2M 3.72%
2,944,349
– –
PCVX icon
10
Vaxcyte
PCVX
$8.9B
$58.2M 3.47%
1,164,405
-233,000
-17% -$11M
RYTM icon
11
Rhythm Pharmaceuticals
RYTM
$7.38B
$35.7M 2.13%
2,167,222
+2,483
+0.1% +$44.8K
BBIO icon
12
BridgeBio Pharma
BBIO
$15B
$34.2M 2.04%
1,988,876
+817,226
+70% +$12.3M
TARS icon
13
Tarsus Pharmaceuticals
TARS
$3.15B
$32.3M 1.93%
1,787,527
– –
ALPN
14
DELISTED
Alpine Immune Sciences Inc
ALPN
$30.7M 1.83%
2,985,757
– –
KALV
15
DELISTED
KalVista Pharmaceuticals
KALV
$29.1M 1.74%
3,238,859
– –
IRON icon
16
Disc Medicine
IRON
$3.07B
$29.1M 1.74%
+655,000
New +$23.2M
CRNX icon
17
Crinetics Pharmaceuticals
CRNX
$9B
$25.5M 1.52%
1,414,823
– –
RVMD icon
18
Revolution Medicines
RVMD
$44.6B
$22.9M 1.37%
854,484
– –
THRX
19
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$21M 1.25%
2,248,194
– –
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$5.02B
$20.5M 1.23%
857,338
– –
MRUS
21
DELISTED
Merus
MRUS
$19.7M 1.17%
746,479
– –
ANAB icon
22
AnaptysBio
ANAB
$1.67B
$18.3M 1.09%
899,700
– –
COGT icon
23
Cogent Biosciences
COGT
$6.02B
$17.8M 1.06%
1,501,383
-657,771
-30% -$7.55M
TYRA icon
24
Tyra Biosciences
TYRA
$1.49B
$17.5M 1.05%
1,028,013
-393,297
-28% -$5.7M
JBIO
25
Jade Biosciences
JBIO
$1.33B
$17.1M 1.02%
28,425
+18,765
+194% +$12M
1
2 3

Similar funds

AF
Avanza Fonder Stockholm, Sweden $4.59B AUM 41.03% 1-Year Est. Return
BWA
Brave Warrior Advisors New York $4.59B AUM 9.32% 1-Year Est. Return
CCA
Conestoga Capital Advisors Wayne, Pennsylvania $4.6B AUM 16.08% 1-Year Est. Return
AT
Arbejdsmarkedets Tillaegspension Hilleroed $4.6B AUM
SLG
Silver Lake Group Menlo Park, California $4.58B AUM 24.86% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $4.61B AUM 50.58% 1-Year Est. Return
LP
Longaeva Partners Chicago, Illinois $4.58B AUM 43.91% 1-Year Est. Return
CSP
Cary Street Partners Richmond, Virginia $4.58B AUM 24% 1-Year Est. Return

Frazier Life Sciences Management's Q2 2023 Portfolio in Review

As of Q2 2023, Frazier Life Sciences Management held 53 positions worth $1.67B, up 21% from $1.38B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Frazier Life Sciences Management deployed $59.1M of net new capital in Q2 2023, opening 4 new positions and adding to 12 existing holdings. Its largest new stake was Disc Medicine: 655,000 shares worth $29.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Vaxcyte, an estimated $11M trimmed.

  • Frazier Life Sciences Management's largest Q2 2023 buy was Disc Medicine: 655,000 shares worth $29.1M.
  • Frazier Life Sciences Management added most to NewAmsterdam Pharma in Q2 2023, an estimated $20.3M increase.
  • Frazier Life Sciences Management's biggest Q2 2023 reduction was Vaxcyte, cutting an estimated $11M.
  • Frazier Life Sciences Management fully exited VectivBio Holding AG Ordinary Shares in Q2 2023, selling an estimated $11.6M.
  • Frazier Life Sciences Management's ten largest holdings make up 67% of its $1.67B portfolio in Q2 2023.
  • Frazier Life Sciences Management opened 4 new positions and closed 5 in Q2 2023.
  • Frazier Life Sciences Management's portfolio value rose 21% quarter-over-quarter to $1.67B.

Based on Frazier Life Sciences Management's 13F filing for Q2 2023, filed 14 Aug 2023.